MC
BHVN icon

Matisse Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Matisse Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,000
Closed -$270K – 141
2017
Q4 		$270K Hold
10,000
– – 0.12% 110
2017
Q3 		$374K Hold
10,000
– – 0.18% 83
2017
Q2 		$250K Buy
+10,000
New +$230K 0.13% 98

Other funds holding BHVN

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Matisse Capital's BHVN Position: Q1 2018 in Review

Matisse Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2018, closing a stake of 10,000 shares — an estimated $270K sold.

Matisse Capital first reported a position in BHVN in Q2 2017 and held it in 3 quarters. The position peaked at $374K in Q3 2017. 100 funds tracked by Wall St. Rank hold BHVN as of Q1 2018.

  • Matisse Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2018 after selling out during the quarter.
  • Matisse Capital sold 10,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2018, an estimated $270K.
  • Matisse Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 3 quarters.
  • Matisse Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $374K in Q3 2017.
  • 100 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2018.

Based on Matisse Capital's 13F filing for Q1 2018, filed 30 Apr 2018.